Elucidating the effect of empagliflozin on the cardiac and renal sympathetic outflows in patients with type 2 diabetes
Phase of Trial: Phase IV
Latest Information Update: 11 Dec 2018
At a glance
- Drugs Empagliflozin (Primary)
- Indications Cardiovascular disorders; Coronary artery disease
- Focus Pharmacodynamics
- 05 Dec 2018 Status changed from not yet recruiting to recruiting.
- 14 Mar 2018 Planned initiation date changed from 18 Apr 2017 to 1 Apr 2018.
- 06 Apr 2017 New trial record